Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Sep 2;13(5):86-89.
doi: 10.55729/2000-9666.1236. eCollection 2023.

Metaxalone-induced Immune Hemolytic Anemia

Afoma Onyechi  1 , Jessica Ohemeng-Dapaah  1 , Rushin Patel  1 , Eduzor Onyechi  2 , Mosunmoluwa Oyenuga  3 , Sara Sartaj  1 , Mudresh Mehta  4 , Alexandre Lacasse  1 , Ikechukwu E Anyadibe  2
Affiliations
Case Reports

Metaxalone-induced Immune Hemolytic Anemia

Afoma Onyechi et al. J Community Hosp Intern Med Perspect. .

Abstract

Drug-induced immune hemolytic anemia (DIIHA) is a relatively uncommon cause of anemia, and its diagnosis can be challenging. Although beta-lactam antimicrobial agents are often associated with DIIHA, any medication can potentially cause it. We describe a patient presenting with yellow skin discoloration and orange-colored urine after starting metaxalone for treatment of lumbosacral sprain. Laboratory studies were consistent with warm hemolytic anemia. Symptoms improved remarkably after discontinuation of metaxalone, coupled with initiation of glucocorticoids and rituximab.

Keywords: Drug induced immune hemolytic anemia; Hemolysis; Metaxalone.

PubMed Disclaimer

Conflict of interest statement

Conflict of interests None.

Figures

Fig. 1
Fig. 1
Lab values. Orange arrows – Initiation of prednisone. Green arrows – Initiation of rituximab therapy. Black arrows – Initiation of prednisone taper. Yellow arrows – Completion of rituximab therapy.
See this image and copyright information in PMC

References

    1. Kalfa TA. Warm antibody autoimmune hemolytic anemia. Hematology. 2016;2016(1):690–697. doi: 10.1182/asheducation-2016.1.690. - DOI - PMC - PubMed
    1. Michel M. Classification and therapeutic approaches in autoimmune hemolytic anemia: an update. Expert Rev Hematol. 2011;4(6):607–618. doi: 10.1586/ehm.11.60. - DOI - PubMed
    1. Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre. BMJ. 1981;282(6281):2023–2027. doi: 10.1136/bmj.282.6281.2023. - DOI - PMC - PubMed
    1. Aladjidi N, Leverger G, Leblanc T, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica. 2011;96(5):655–663. doi: 10.3324/haematol.2010.036053. - DOI - PMC - PubMed
    1. Sokol RJ, Hewitt S, Stamps BK, Hitchen PA. Autoimmune haemolysis in childhood and adolescence. Acta Haematol. 1984;72(4):245–257. doi: 10.1159/000206397. - DOI - PubMed

Publication types

LinkOut - more resources